You have changed your country from  to  . Please be aware that this will change the currency in the purchasing process.

Anti-Met (c-Met) antibody (ab74217)

Submit an Abreview Q&A (1)

Overview

  • Product nameAnti-Met (c-Met) antibodySee all Met (c-Met) primary antibodies ...
  • Description
    Rabbit polyclonal to Met (c-Met)
  • Tested applicationsIHC-P, WB more details
  • Species reactivity
    Reacts with: Human
  • Immunogen

    A synthetic peptide from C terminus of human Met (c-Met) protein

  • Positive controlA431 cells; Paraffin embedded human breast and ovarian carcinoma tissues.

Properties

Applications

Our Abpromise guarantee covers the use of ab74217 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Notes
IHC-P
WB
  • Application notesIHC-P: 1/50 for 10 min at RT.
    Staining of formalin-fixed tissues requires boiling tissue sections in 10mM citrate buffer, pH 6.0 for 10 min followed by cooling at RT for 20 min.

    WB: Use at a concentration of 2 - 4 µg/ml ml for 2hrs at RT. Predicted molecular weight: 156 kDa.


    Not yet tested in other applications.
    Optimal dilutions/concentrations should be determined by the end user.

    • Target

    • FunctionReceptor for hepatocyte growth factor and scatter factor. Has a tyrosine-protein kinase activity. Functions in cell proliferation, scattering, morphogenesis and survival.
    • Involvement in diseaseNote=Activation of MET after rearrangement with the TPR gene produces an oncogenic protein.
      Note=Defects in MET may be associated with gastric cancer.
      Defects in MET are a cause of hepatocellular carcinoma (HCC) [MIM:114550].
      Defects in MET are a cause of renal cell carcinoma papillary (RCCP) [MIM:605074]. It is a subtype of renal cell carcinoma tending to show a tubulo-papillary architecture formed by numerous, irregular, finger-like projections of connective tissue. Renal cell carcinoma is a heterogeneous group of sporadic or hereditary carcinoma derived from cells of the proximal renal tubular epithelium. It is subclassified into common renal cell carcinoma (clear cell, non-papillary carcinoma), papillary renal cell carcinoma, chromophobe renal cell carcinoma, collecting duct carcinoma with medullary carcinoma of the kidney, and unclassified renal cell carcinoma.
      Note=A common allele in the promoter region of the MET shows genetic association with susceptibility to autism in some families. Functional assays indicate a decrease in MET promoter activity and altered binding of specific transcription factor complexes.
      Note=MET activating mutations may be involved in the development of a highly malignant, metastatic syndrome known as cancer of unknown primary origin (CUP) or primary occult malignancy. Systemic neoplastic spread is generally a late event in cancer progression. However, in some instances, distant dissemination arises at a very early stage, so that metastases reach clinical relevance before primary lesions. Sometimes, the primary lesions cannot be identified in spite of the progresses in the diagnosis of malignancies.
    • Sequence similaritiesBelongs to the protein kinase superfamily. Tyr protein kinase family.
      Contains 3 IPT/TIG domains.
      Contains 1 protein kinase domain.
      Contains 1 Sema domain.
    • DomainThe kinase domain is involved in SPSB1 binding.
    • Post-translational
      modifications      Dephosphorylated by PTPRJ at Tyr-1349 and Tyr-1365.
    • Cellular localizationMembrane.

      • Target information above from: UniProt accession P08581 The UniProt Consortium
      The Universal Protein Resource (UniProt) in 2010
      Nucleic Acids Res. 38:D142-D148 (2010) .

      Information by UniProt
    • Database links
      • Alternative names
          AUTS9 antibodyc met antibodycmet antibody
          D249 antibodyHepatocyte growth factor receptor antibodyHepatocyte growth factor receptor Precursor antibodyHGF antibodyHGF receptor antibodyHGF SF receptor antibodyHGF/SF receptor antibodyHGFR antibodyMET antibodyMet proto oncogene tyrosine kinase antibodyMet proto-oncogene (hepatocyte growth factor receptor) antibodyMet proto-oncogene antibodyMet protooncogene antibodyMET_HUMAN antibodyOncogene MET antibodyPar4 antibodyProto-oncogene c-Met antibodyRCCP2 antibodyRenal cell carcinoma papillary 2 gene antibodyScatter factor receptor antibodySF receptor antibodyTyrosine-protein kinase Met antibody
        see all

      Anti-Met (c-Met) antibody images

      • Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Met (c-Met) antibody (ab74217)
        Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Met (c-Met) antibody (ab74217)
        ab74217 at 1/50 dilution staining Met (c-Met) in human ovarian carcinoma by Immunohistochemistry, Formalin-fixed, Paraffin-embedded tissue.

      References for Anti-Met (c-Met) antibody (ab74217)

      ab74217 has not yet been referenced specifically in any publications.

      Publishing research using ab74217 ? Please let us know so that we can cite the reference in this datasheet

      Product Wall

      Submit an Abreview for ab74217 Submit a Question for ab74217

      Displaying 1 - 1 of 1 results for Abreviews and Q&A

      10
      Votes: Highest First

      What are positve control for this ab?

      Thank you for contacting us.

      I have pasted the link to Human Protein Atlas database which shows MET positive staining of various human tissue sections. The red colour represents high staining. You can select positive control section based on th...

      Read More

      Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"